The role of BRCA mutation testing in determining breast cancer therapy

Nature Reviews Clinical Oncology

Volumn 7, Issue 12, 2010, Pages 708-715

  Trainer, Alison H ^a   Lewis, Craig R ^b   Tucker, Kathy ^c   Meiser, Bettina ^b   Friedlander, Michael ^d   Ward, Robyn L ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXEMESTANE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM COMPLEX; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FAMILIAL CANCER; FAMILY HISTORY; GENE IDENTIFICATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; MUTATIONAL ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CASE MANAGEMENT; ETHNIC GROUPS; FEMALE; GENE EXPRESSION PROFILING; GENES, BRCA1; GENES, BRCA2; GENES, DOMINANT; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; INDIVIDUALIZED MEDICINE; MASTECTOMY; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; PROGNOSIS; RISK;

EID: 78649662629     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.175     Document Type: Review

References (116)

1. Ardern-Jones, A., Kenen, R. & Eeles, R. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur. J. Cancer Care (Engl.) 14, 272-281 (2005).
2. Antoniou, A. C. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer 98, 1457-1466 (2008).
3. Berry, D. A. et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol. 20, 2701-2712 (2002).
4. Evans, D. G., Lalloo, F., Wallace, A. & Rahman, N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J. Med. Genet. 42, e39 (2005).
5. [No authors listed] American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21, 2397-2406 (2003).
6. Kang, H. H. et al. Evaluation of models to predict BRCA germline mutations. Br. J. Cancer 95, 914-920 (2006).
7. Møller, P. et al. Genetic epidemiology of BRCA mutations\family history detects less than 50% of the mutation carriers. Eur. J. Cancer 43, 1713-1717 (2007).
8. De Sanjosé, S. et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int. J. Cancer 106, 588-593 (2003).
9. Weitzel, J. N. et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297, 2587-2595 (2007).
10. Malone, K. E. et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88, 1393-1402 (2000).
11. Haffty, B. G., Silber, A., Matloff, E., Chung, J. & Lannin, D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J. Med. Genet. 43, 133-137 (2006).
12. Hamann, U. et al. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur. J. Hum. Genet. 11, 464-467 (2003).
13. Robson, M. et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet. Test. 1, 47-51 (1997).
14. Górski, B. et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer 110, 683-686 (2004).
15. Verhoog, L. C. et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur. J. Cancer 37, 2082-2090 (2001).
16. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
17. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
18. Reis-Filho, J. S. & Tutt, A. N. Triple negative tumours: a critical review. Histopathology 52, 108-118 (2008).
19. Cleator, S., Heller, W. & Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8, 235-244 (2007).
20. Lakhani, S. R. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11, 5175-5180 (2005).
21. Foulkes, W. D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95, 1482-1485 (2003).
22. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
23. Mavaddat, N., Rebbeck, T. R., Lakhani, S. R., Easton, D. F. & Antoniou, A. C. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 12, R28 (2010).
24. Young, S. R. et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9, 86 (2009).
25. Watson, P. et al. Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers. J. Clin. Oncol. 27, 3894-3900 (2009).
26. James, P. A. et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J. Clin. Oncol. 24, 707-715 (2006).
27. Metcalfe, K. A. et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br. J. Cancer 100, 421-425 (2009).
28. Kauff, N. D. et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J. Natl Cancer Inst. 97, 1382-1384 (2005).
29. Haffty, B. G. et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359, 1471-1477 (2002).
30. Garcia-Etienne, C. A. et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann. Surg. Oncol. 16, 3380-3387 (2009).
31. Kip1 protein levels independently predict outcome after breast cancer. J. Clin. Oncol. 18, 4045-4052 (2000).
32. Robson, M. et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J. Natl Cancer Inst. 91, 2112-2117 (1999).
33. Brekelmans, C. T. et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann. Oncol. 17, 391-400 (2006).
34. Haffty, B. G. & Lannin, D. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? Eur. J. Cancer 40, 1105-1108 (2004).
35. Pierce, L. J. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol. 24, 2437-2443 (2006).
36. Verhoog, L. C. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351, 316-321 (1998).
37. Verhoog, L. C. et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J. Clin. Oncol. 17, 3396-3402 (1999).
38. Foulkes, W. D. et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann. Oncol. 11, 307-313 (2000).
39. Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Meijers-Heijboer, E. J. & Klijn, J. G. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br. J. Cancer 83, 384-386 (2000).
40. Graeser, M. K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 27, 5887-5892 (2009).
41. Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8-R17 (2004).
42. Pierce, L. J. et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J. Clin. Oncol. 18, 3360-3369 (2000).
43. Robson, M. et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103, 44-51 (2005).
44. Eccles, D. et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam. Cancer 1, 65-72 (2001).
45. Kirova, Y. M. et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41, 2304-2311 (2005).
46. Metcalfe, K. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22, 2328-2335 (2004).
47. Gronwald, J. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118, 2281-2284 (2006).
48. Schwartz, G. F. et al. Proceedings of the international consensus conference on breast cancer risk, genetics, and risk management, April, 2007. Cancer 113, 2627-2637 (2008).
49. Nieuwenhuis, B. et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int. J. Radiat. Biol. 78, 285-295 (2002).
50. Lovelock, P. K. et al. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability. Breast Cancer Res. Treat. 104, 257-266 (2007).
51. Gaffney, D. K. et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother. Oncol. 47, 129-136 (1998).
52. Shanley, S. et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin. Cancer Res. 12, 7025-7032 (2006). (Pubitemid 44974499)
53. Leong, T. et al. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 48, 959-965 (2000).
54. Peralta, E. A. et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am. J. Surg. 180, 439-445 (2000).
55. Lostumbo, L., Carbine, N., Wallace, J. & Ezzo, J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD002748. doi:10.1002/14651858.CD002748.pub2 (2004).
56. McDonnell, S. K. et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J. Clin. Oncol. 19, 3938-3943 (2001).
57. van Sprundel, T. C. et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer 93, 287-292 (2005).
58. Schwartz, M. D. et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J. Clin. Oncol. 22, 1823-1829 (2004).
59. Evans, D. G. et al. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur. J. Surg. Oncol. 31, 1112-1118 (2005)
60. Stolier, A. J., Fuhrman, G. M., Mauterer, L., Bolton, J. S. & Superneau, D. W. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J. 10, 475-480 (2004).
61. Tuttle, T. M., Habermann, E. B., Grund, E. H., Morris, T. J. & Virnig, B. A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 25, 5203-5209 (2007).
62. McLaughlin, C. C., Lillquist, P. P. & Edge, S. B. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer 115, 5404-5412 (2009).
63. Anders, C. K. et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J. Clin. Oncol. 26, 3324-3330 (2008).
64. Bauer, K. R. et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109, 1721-1728 (2007).
65. Chetrit, A. et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin. Oncol. 26, 20-25 (2008).
66. Brekelmans, C. T. et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer 43, 867-876 (2007).
67. Budroni, M. et al. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer 9, 62 (2009).
68. Bonadona, V. et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res. Treat. 101, 233-245 (2007).
69. Eerola, H. et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int. J. Cancer 93, 368-372 (2001).
70. El-Tamer, M. et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann. Surg. Oncol. 11, 157-164 (2004).
71. Goffin, J. R. et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97, 527-536 (2003).
72. Rennert, G. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357, 115-123 (2007). (Pubitemid 47057729)
73. Hamann, U. & Sinn, H. P. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res. Treat. 59, 185-192 (2000).
74. Loman, N. et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur. J. Cancer 36, 1365-1373 (2000).
75. Jóhannsson, O. T., Ranstam, J., Borg, A. & Olsson, H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol. 16, 397-404 (1998).
76. Seynaeve, C. et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur. J. Cancer 40, 1150-1158 (2004).
77. Robson, M. et al. BRCA-associated breast cancer in young women. J. Clin. Oncol. 16, 1642-1649 (1998).
78. Stoppa-Lyonnet, D. et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J. Clin. Oncol. 18, 4053-4059 (2000).
79. Møller, P. et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int. J. Cancer 101, 555-559 (2002).
80. Lee, E. H. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res. Treat. 122, 11-25 (2010).
81. Eccles, D. et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 7, 160 (2007).
82. Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 8, 735-748 (2007).
83. Jasin, M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21, 8981-8993 (2002).
84. Taniguchi, T. & D'Andrea, A. D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107, 4223-4233 (2006).
85. Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
86. Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R. & Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899-23903 (2000).
87. Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925 (2008).
88. Byrski, T. et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 108, 289-296 (2008).
89. Kurebayashi, J. et al. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 26, 695-701 (2006).
90. Quinn, J. E. et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 13, 7413-7420 (2007).
91. Lee, H. et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell 4, 1-10 (1999).
92. Quinn, J. E. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63, 6221-6228 (2003).
93. Byrski, T. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115, 359-363 (2009).
94. Chappuis, P. O. et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 39, 608-610 (2002).
95. Hubert, A. et al. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam. Cancer 8, 173-177 (2009).
96. Wong Wong Keet, A. et al. Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int. J. Cancer 125, 2236-2238 (2009).
97. Silva, E. & Lynch, H. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations. Breast J. 12, 280-281 (2006).
98. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
99. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
100. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
101. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
102. Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25, 1329-1333 (2007).
103. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
104. Metcalfe, K. A. et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol. 96, 222-226 (2005).
105. van der Velde, N. M. et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int. J. Cancer 124, 919-923 (2009).
106. Mourits, M. J. & de Bock, G. H. Managing hereditary ovarian cancer. Maturitas 64, 172-176 (2009).
107. Higgins, M. J. & Davidson, N. E. What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? Curr. Oncol. Rep. 11, 45-50 (2009).
108. Bianco, A. R. et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br. J. Cancer 63, 799-803 (1991).
109. Castiglione-Gertsch, M. et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst. 95, 1833-1846 (2003).
110. Eisen, A. et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol. 23, 7491-7496 (2005). (Pubitemid 46291812)
111. Kramer, J. L. et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J. Clin. Oncol. 23, 8629-8635 (2005).
112. Schlich-Bakker, K. J. et al. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur. J. Cancer 42, 2722-2728 (2006).
113. Schlich-Bakker, K. J. et al. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res. Treat. 109, 507-514 (2008).
114. Schlich-Bakker, K. J., ten Kroode, H. F., Wárlám-Rodenhuis, C. C., van den Bout, J. & Ausems, M. G. Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet. Med. 9, 766-777 (2007).
115. Wárlám-Rodenhuis, C. C., Koot, V. C., van der Luijt, R. B., Vasen, H. F. & Ausems, M. G. A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients. Eur. J. Cancer 41, 1409-1415 (2005).
116. Weitzel, J. N. et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch. Surg. 138, 1323-1328 (2003).